학술논문

Systemic thrombolytic therapy in patients with intermediate-high-risk pulmonary embolism.
Document Type
Abstract
Source
Cardiologia Croatica. Sep/Oct2022, Vol. 17 Issue 9/10, p292-292. 1p.
Subject
*THROMBOLYTIC therapy
*PULMONARY embolism
*OLDER people
*CARDIOVASCULAR diseases
*POPULATION aging
Language
ISSN
1848-543X
Abstract
Pulmonary embolism remains the one of the commonest cardiovascular disease, the severity of which is variable and can be lethal. The incidence is expected to increase due to the aging population. Intermediate-high risk pulmonary embolism is characterized by hemodynamical stability, but elevated mortality risk and both radiographic and laboratory signs of right heart strain. Thrombolysis remains a possible life saving treatment option but bears an increased risk of potentially life-threatening hemorrhage. Optimal treatment is still not established.1-3 We present a series of intermediate-high risk patients treated in our hospital with thrombolytic therapy (n=4, 2 male, median age 58.5) and compare relevant direct and indirect values of right ventricular load before and after treatment (Table 1). We also provide a summary of our clinical approach in light of current guidelines and two meta-analyses. [ABSTRACT FROM AUTHOR]